Cyclosporine microemulsion (Neoral) versus tacrolimus (FK506) as maintenance therapy in kidney transplant patients.
Abou-Jaoude
M M
MM
St-Georges Hospital, Beirut, Lebanon.
Irani-Hakime
N
N
Ghantous
I
I
Najm
R
R
Afif
C
C
Almawi
W Y
WY
D000328:Adult; D000911:Antibodies, Monoclonal / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum / Q000627:therapeutic use; D001786:Blood Glucose / Q000378:metabolism; D002102:Cadaver; D016572:Cyclosporine / Q000627:therapeutic use*; D000077561:Daclizumab; D004359:Drug Therapy, Combination; D005260:Female; D005500:Follow-Up Studies; D006084:Graft Rejection / Q000453:epidemiology; D006650:Histocompatibility Testing; D006801:Humans; D007074:Immunoglobulin G / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000627:therapeutic use; D016030:Kidney Transplantation / Q000276:immunology*; D008055:Lipids / Q000097:blood; D019520:Living Donors; D008297:Male; D008875:Middle Aged; D016559:Tacrolimus / Q000627:therapeutic use*; D014019:Tissue Donors
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D000961:Antilymphocyte Serum; D001786:Blood Glucose; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D008055:Lipids; D016572:Cyclosporine; D000077561:Daclizumab; D016559:Tacrolimus